User profiles for K. D. Lewis
Karl Lewisuniversity of colorado Verified email at ucdenver.edu Cited by 28710 |
[HTML][HTML] Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib
Background Approximately 50% of melanomas harbor activating (V600) mutations in the
serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032…
serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032…
[HTML][HTML] Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
…, FS Hodi, J Schachter, AC Pavlick, KD Lewis… - The lancet …, 2015 - thelancet.com
Background Patients with melanoma that progresses on ipilimumab and, if BRAF V600
mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the …
mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the …
[HTML][HTML] Efficacy and safety of vismodegib in advanced basal-cell carcinoma
Background Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell
carcinoma. Although most basal-cell carcinomas are treated surgically, no effective …
carcinoma. Although most basal-cell carcinomas are treated surgically, no effective …
In vivo enhancer analysis of human conserved non-coding sequences
…, M Shoukry, S Minovitsky, I Dubchak, A Holt, KD Lewis… - Nature, 2006 - nature.com
Identifying the sequences that direct the spatial and temporal expression of genes and
defining their function in vivo remains a significant challenge in the annotation of vertebrate …
defining their function in vivo remains a significant challenge in the annotation of vertebrate …
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
…, GP Linette, M Milella, I Brownell, KD Lewis… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
[HTML][HTML] PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
…, A Guminski, A Hauschild, KD Lewis… - … England Journal of …, 2018 - Mass Medical Soc
Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, …
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, …
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
GS Falchook, KD Lewis, JR Infante, MS Gordon… - The lancet …, 2012 - thelancet.com
Background MEK is a member of the MAPK signalling cascade that is commonly activated
in melanoma. Direct inhibition of MEK blocks cell proliferation and induces apoptosis. We …
in melanoma. Direct inhibition of MEK blocks cell proliferation and induces apoptosis. We …
Phylogenetic shadowing of primate sequences to find functional regions of the human genome
Nonhuman primates represent the most relevant model organisms to understand the biology
of Homo sapiens. The recent divergence and associated overall sequence conservation …
of Homo sapiens. The recent divergence and associated overall sequence conservation …
[HTML][HTML] Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF …
Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for …
activation of MEK. The purpose of this study was to determine the response rate (RR) for …
[PDF][PDF] Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
…, PA Ott, RK Amaravadi, KD Lewis… - Journal of clinical …, 2013 - researchgate.net
Purpose To assess pharmacodynamic effects and intrinsic and acquired resistance
mechanisms of the BRAF inhibitor vemurafenib in BRAFV600-mutant melanoma, leading to an …
mechanisms of the BRAF inhibitor vemurafenib in BRAFV600-mutant melanoma, leading to an …